Oncolytics Biotech (ONCY) Income towards Parent Company (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Income towards Parent Company for 17 consecutive years, with -$10.8 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Income towards Parent Company fell 55.2% year-over-year to -$10.8 million; the TTM figure through Dec 2025 stood at -$15.6 million (up 12.64% YoY), while the FY2025 annual figure was -$28.8 million, down 25.2% from the prior year.
• Income towards Parent Company retreated to -$10.8 million in Q3 2025 per ONCY's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $5.9 million in Q2 2021 and bottomed at -$37.8 million in Q4 2023.
• Historically, Income towards Parent Company has averaged -$8.4 million across 5 years, with a median of -$5.2 million in 2024.
• On a YoY basis, Income towards Parent Company climbed as much as 217.99% in 2021 and fell as far as 230.26% in 2021.
• Oncolytics Biotech's Income towards Parent Company stood at -$35.6 million in 2021, then climbed by 15.98% to -$29.9 million in 2022, then declined by 26.16% to -$37.8 million in 2023, then jumped by 84.89% to -$5.7 million in 2024, then tumbled by 89.8% to -$10.8 million in 2025.
• Business Quant data shows ONCY's Income towards Parent Company at -$10.8 million in Q3 2025, -$4.8 million in Q2 2025, and -$5.7 million in Q4 2024.